We're productizing a regenerative cell production methodology for the on-demand manufacturing of autologous regenerative cell treatments for severe spinal cord and peripheral nerve damage.
AutoRegenic is a precision biomedicine manufacturing company that is validating, productizing and commercializing a personalized tissue regenerative treatment for severe spinal cord injury (SCI) and peripheral neve injury (PNI), specifically for victims of quadriplegia and paraplegia.
SCI and PNI afflicts over 300,000 people per year, joining the over 20 million existing victims whose treatments cost between USD100,000 and USD200,000 and whose lifetime healthcare care costs range from USD5 million to USD5 million.
The AutoRegenic Neuronal Graft is a product of in-vitro manufacturing of an autologous regenerative spinal cord or peripheral nerve segment for implantation in a bio-fabrication 3D scaffold. The manufacturing protocol is the outcome of advanced tissue engineering techniques, materials and procedures encompassing well established cell isolation, expansion and induction methodologies executed in a highly-formulated, practiced, precise and proven manner.
The result of 32 cumulative years of multidisciplinary applied R&D, the AutoRegenic solution is an invasive and comprehensive neurosurgical intervention that promises to offer broadly versatile clinical utility, which has been proven safe and effective in restoring sensory and motor functionality in three experimental compassionate care treatments of three human paraplegics and quadriplegics patients to date.
Our team is comprised of experienced entrepreneurs from the biomedical, pharmaceutical, donor registry, technology, regulatory and marketing fields, supported by a world-class scientific advisory board, including international experts in the field of regenerative medicine and transplantation, and uniquely skilled laboratory technicians.
We are productizing an unique set of laboratory techniques, processes, materials, and international logistics for producing a personalized graft in a 3D biomaterial scaffold that promises to become a safe, effective and affordable solution for nerve regeneration through transplantation in PNI and SCI patients.
Following years of unique insights into regenerative therapies, the leadership team has defined a path for translating proven applied R&D and commercializing biomedicines and has assembled a set luminary supporters and advisory spanning the scientific and medical academic, as well as clinical practice, fields.